Explore chapters and articles related to this topic
Current developments in lantibiotic discovery for treating Clostridium difficile infection
Published in Expert Opinion on Drug Discovery, 2019
Stephanie Kate Sandiford
Microbisporicin is produced by Microbispora sp. as two structurally similar polypeptides (A1 and A2) containing two unusual post-translational modifications 5-chloro-tryptophan and mono (in A2) or bis-hydroxylated (in A1) proline. NAI-107 exerts its activity by binding to lipid II and other bactoprenol-bound precursors impairing membrane function thus resulting in bacteriocidal activity [68].